Pasithea Therapeutics Corp. (KTTA)

Price & Market Data

Price: $0.717

Daily Change: -$0.004 / 0.56%

Daily Range: $0.695 - $0.741

Market Cap: $23,383,432

Daily Volume: 334,625

Performance Metrics

1 Week: -11.26%

1 Month: 2.44%

3 Months: -11.26%

6 Months: 98.19%

1 Year: -22.84%

YTD: -44.54%

About Pasithea Therapeutics Corp. (KTTA)

Quick market take on Pasithea Therapeutics Corp. (KTTA). Current price: 0.717, daily change: -$0.004 / 0.56%. Market cap: 23,383,432. Performance over 1-week and 1-month.

Company Details

Employees: 5

Sector: Health technology

Industry: Pharmaceuticals: major

Country: United States

Details

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Selected stocks

Zeta Network Group (ZNB)

SunCar Technology Group Inc. (SDA)

Marqeta, Inc. (MQ)

NexGel, Inc (NXGL)

Traws Pharma, Inc. (TRAW)